logo
American Lithium Announces Upsizing of Private Placement

American Lithium Announces Upsizing of Private Placement

Not for distribution to U.S. news wire services or dissemination in the United States
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) — American Lithium Corp. ('American Lithium' or the 'Company') (TSX-V:LI | OTCQX:AMLIF | Frankfurt:5LA1) is pleased to announce that due to significant interest, the Company has requested and received conditional approval from the TSX Venture Exchange (the 'TSXV') to increase the size of its previously announced non-brokered private placement and will now offer up to 34,814,815 units (the 'Units') of the Company at a price of $0.27 per Unit for aggregate gross proceeds of up to $9,400,000 (the 'Private Placement').
Each Unit issued pursuant to the Private Placement will consist of one common share (a 'Common Share') in the capital of the Company and one Common Share purchase warrant (a 'Warrant'). Each warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.50 for 36 months from the closing date of the Private Placement.
The Private Placement is subject to certain closing restrictions, including, but not limited to, the receipt of all necessary regulatory approvals and the approval of the TSXV.
The Private Placement will be made to qualified investors in such provinces of Canada as the Company may designate, and otherwise in those jurisdictions where the Private Placement can lawfully be made. All securities issued pursuant to the Private Placement will be subject to a four-month hold and one day hold period in accordance with applicable Canadian securities laws.
This news release shall not constitute an offer to sell or the solicitation of an offer to sell nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About American Lithium
American Lithium is developing two of the world's largest, advanced-stage lithium projects, along with the largest undeveloped uranium project in Latin America. They include the TLC claystone lithium project in Nevada, the Falchani hard rock lithium project and the Macusani uranium deposit, both in southern Peru. All three projects have been through robust preliminary economic assessments, exhibit significant expansion potential and enjoy strong community support.
For more information, please contact the Company at
info@americanlithiumcorp.com
or visit our website at
www.americanlithiumcorp.com
.
Follow us on
Facebook,
Twitter
and
LinkedIn
.
On behalf of the Board of Directors of American Lithium Corp.
'Alex
Tsakumis'
Interim CEO
Tel: 604 428 6128
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Statement Regarding Forward Looking Information
This news release contains certain forward-looking information and forward-looking statements (collectively 'forward-looking statements') within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the terms of the Units and Warrants, statements regarding the Private Placement and the issuance of securities thereunder, the aggregate amount of proceeds to be raised and the use of proceeds.
Forward-looking
statements
are
frequently
identified
by such words as 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend', 'indicate', 'scheduled', 'target',
'goal',
'potential',
'subject',
'efforts',
'option'
and
similar
words,
or
the
negative
connotations thereof, referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management and are not, and cannot be, a guarantee of future results or events. Although American Lithium believes that the current opinions and expectations reflected in such forward-looking statements are reasonable based on information available at the time, undue reliance should
not
be
placed
on
forward-looking
statements
since
American
Lithium
can
provide
no
assurance
that such opinions and expectations will prove to be correct. All forward-looking statements are inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including risks, uncertainties and assumptions related to: American Lithium's ability to achieve its stated goals, which could have a material adverse impact on many aspects of American Lithium's businesses including but not limited to: the
ability
to
access
mineral
properties
for
indeterminate
amounts
of
time,
the
health
of
the
employees
or consultants resulting in delays or diminished capacity, social or political instability in Peru which in turn could
impact
American
Lithium's
ability
to
maintain
the
continuity
of
its
business
operating
requirements, may
result
in
the
reduced
availability
or
failures
of
various
local
administration
and
critical
infrastructure, reduced demand for the American Lithium's potential products, availability of materials, global travel restrictions, and the availability of insurance and the associated costs; the ongoing ability to work cooperatively with stakeholders, including but not limited to local communities and all levels of government; the potential for delays in exploration or development activities; the interpretation of drill results, the geology, grade and continuity of mineral deposits; the possibility that any future exploration, development or mining results will not be consistent with our expectations; risks that permits will not be obtained as planned or
delays in
obtaining permits;
mining and development
risks, including risks
related to accidents, equipment breakdowns, labour disputes (including work stoppages, strikes and loss of personnel) or other unanticipated difficulties with or interruptions in exploration and development; risks related
to
commodity
price
and
foreign
exchange
rate
fluctuations;
risks
related
to
foreign
operations;
the cyclical nature of the industry in which American Lithium operates; risks related to failure to obtain adequate financing on a timely basis and on acceptable terms or delays in obtaining governmental approvals;
risks
related
to
environmental
regulation
and liability; political and
regulatory risks
associated with mining and exploration; risks related to the uncertain global economic environment and the effects upon the global market generally, any of which could continue to negatively affect global financial markets, including the trading price of American Lithium's shares and could negatively affect American Lithium's ability to raise capital and may also result in additional and unknown risks or liabilities to American Lithium. Other risks and uncertainties related to prospects, properties and business strategy of American Lithium are identified in the 'Risk Factors' section of American Lithium's Management's Discussion and Analysis filed on June 27, 2025, and in recent securities filings available at
www.sedarplus.ca.
Actual events or results may differ materially from those projected in the forward- looking statements. American Lithium undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward- looking statements.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Physical Therapy Reports Second Quarter 2025 Results
U.S. Physical Therapy Reports Second Quarter 2025 Results

Business Wire

time7 minutes ago

  • Business Wire

U.S. Physical Therapy Reports Second Quarter 2025 Results

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. ('USPH' or the 'Company') (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the three and six months ended June 30, 2025. FINANCIAL HIGHLIGHTS Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles ('GAAP') measure, was $26.9 million for the three months ended June 30, 2025 ('2025 Second Quarter'), an increase of $4.7 million, or 21.4%, from $22.1 million for the three months ended June 30, 2024 ('2024 Second Quarter') primarily driven by higher patient visits. Net income attributable to USPH's shareholders ('USPH Net Income'), a GAAP measure, was $12.4 million for the 2025 Second Quarter compared to $7.5 million for the 2024 Second Quarter. In accordance with GAAP, the revaluation of noncontrolling interest, net of taxes, is not included in net income but is charged directly to retained earnings. However, this change is included in the computation of earnings per share. Earnings per share was $0.58 for the 2025 Second Quarter compared to $0.47 for the 2024 Second Quarter. Operating Results (1), a non-GAAP measure, was $12.4 million for the 2025 Second Quarter compared to $11.0 million for the 2024 Second Quarter, an increase of 11.8% over the same period. On a per share basis, Operating Results was $0.81 for the 2025 Second Quarter compared to $0.73 for the 2024 Second Quarter. Total revenue from physical therapy operations for the 2025 Second Quarter increased $24.8 million, or 17.3%, to $168.3 million. Net rate per patient visit for the 2025 Second Quarter was $105.33 up from $105.05 for the 2024 Second Quarter, despite the approximate 2.9% Medicare rate reduction which went into effect on January 1, 2025. Total patient visits were 1,558,756 for the 2025 Second Quarter, a 16.7% increase from the 2024 Second Quarter. Total patient visits includes 28,493 home-care visits, which the Company will break out separately each period going forward. For the six months ended June 30, 2025, the Company had 3,002,561 total patient visits, which includes 51,436 home-care visits. There were no home-care visits in the first six months of 2024. Average daily patient visits per clinic, which does not include home-care visits, was an all-time high of 32.7 for the 2025 Second Quarter compared to 30.6 for the 2024 Second Quarter. Industrial injury prevention services ('IIP') revenue was $29.1 million for the 2025 Second Quarter, an increase of 22.6% as compared to the 2024 Second Quarter. IIP gross profit was $6.4 million for the 2025 Second Quarter, an increase of $1.3 million, or 25.8%, from $5.1 million for the 2024 Second Quarter. The Company added six clinics and closed four clinics in the 2025 Second Quarter bringing its total owned and/or managed clinic count to 768 as of June 30, 2025, compared to 722 as of June 30, 2024. On April 30, 2025, the Company announced the acquisition of an outpatient home-care physical and speech therapy practice through its 50%-owned subsidiary, MSO Metro, LLC. MSO Metro LLC. acquired 80% of equity interests of the practice, with the original practice owners retaining 20% of equity interests. The practice currently generates approximately $2.1 million in annual revenue. On July 31, 2025, the Company acquired a 60% equity interest in a three-clinic practice with the practice owners retaining a 40% equity interest. The business currently generates $5.3 million in annual revenue and approximately 28,000 in annual visits. The Company's Board of Directors declared a quarterly dividend of $0.45 per share payable on September 12, 2025, to shareholders of record on August 22, 2025. Management increased its guidance for Adjusted EBITDA for full-year 2025 to a range of $93.0 million to $97.0 million. See '2025 Earnings Guidance' below for more information. MANAGEMENT'S COMMENTS Chris Reading, Chief Executive Officer, said, 'Volumes in our physical therapy business remain at record levels while we execute our plan for cost rationalization and improved efficiencies. Our injury prevention business continues a strong growth path, both organically and through carefully added acquisitions, which have broadened our service offerings and increased our exposure to new industry verticals. As a result of our efforts and expected progress we have updated our earnings guidance for the year.' 2025 Second Quarter Versus 2024 Second Quarter Additional supplemental tables of financial and performance metrics are presented on page 16 of this release. Physical Therapy Operations _______________________ (1) See Glossary of Terms - Revenue Metrics for definitions. (2) Includes six clinics added during the 2025 Second Quarter, 14 clinics added during the three months ended March 31, 2025 ("2025 First Quarter") and 96 clinics added during the year ended December 31, 2024. (Owned) (3) Includes three clinics closed during the 2025 Second Quarter, seven clinics closed in the 2025 First Quarter and 45 clinics closed during the year ended December 31, 2024. (Owned) (4) Includes revenues from management contracts. (5) Includes costs from management contracts. (6) Excludes $0.2 million of certain incentive costs related to the Metro acquisition. Please refer to the reconciliation of non-GAAP measures to the most directly comparable GAAP measure on page 15. (7) Not meaningful. Expand Net revenue from physical therapy operations increased $24.8 million, or 17.3%, to $168.3 million for the 2025 Second Quarter from $143.5 million for the 2024 Second Quarter. This growth was due to the increase in visits from the 51 net clinics added since the comparable prior year period and an increase in net rate per patient visit, which reflects the Company's strategic priority of increasing reimbursement rates through contract negotiations with commercial and other payors and the addition of acquisitions with accretive net rate per patient visit. Net rate per patient visit for the 2025 Second Quarter was $105.33 up from $105.05 for the 2024 Second Quarter, despite the approximate 2.9% Medicare rate reduction which went into effect on January 1, 2025. Operating costs from physical therapy operations increased $18.4 million, or 16.0%, to $133.1 million for the 2025 Second Quarter from $114.7 million for the 2024 Second Quarter primarily driven by the 51 net clinics added since the comparable prior year period. Salaries and related costs per visit was $60.08 for the 2025 Second Quarter compared to $59.66 for the 2024 Second Quarter. Total operating costs per visit was $83.95 compared to $84.46 in the prior year quarter, as higher visit volumes did not result in a proportional increase in fixed costs. Gross profit from physical therapy operations for the 2025 Second Quarter was $35.2 million with a gross profit margin of 20.9% compared to $28.8 million with a gross profit margin of 20.1% for the 2024 Second Quarter. Excluding certain incentive costs related to the Metro acquisition of $0.2 million, the adjusted gross profit margin was 21.1% for the 2025 Second Quarter. Industrial Injury Prevention Services IIP revenue increased $5.3 million, or 22.6%, to $29.1 million for the 2025 Second Quarter as compared to $23.7 million for the 2024 Second Quarter. Gross profit from IIP operations for the 2025 Second Quarter increased $1.3 million, or 25.8%, to $6.4 million from $5.1 million for the 2024 Second Quarter. Gross profit margin from IIP operations was 22.0% for the 2025 Second Quarter compared to 21.4% for the 2024 Second Quarter. Excluding the IIP acquisition made in April 2024, IIP revenue increased by $4.0 million or 18.4% in the 2025 Second Quarter and gross profit increased $1.0 million, or 21.8% in the 2025 Second Quarter over the comparable prior year period. Corporate Office and Other Expenses Corporate office costs increased to $17.5 million for the 2025 Second Quarter from $14.2 million for the 2024 Second Quarter, primarily to support the larger number of clinics, as well as acquisition integration costs and costs associated with the implementation of a new financial and human resources system. Implementation costs associated with the new financial and human resources system are expected to continue through the end of 2026. As a ratio to net revenue, corporate office costs was 8.9% for the 2025 Second Quarter compared to 8.5% for the 2024 Second Quarter. Excluding the acquisition integration costs and the costs associated with the implementation of the new financial and human resources system of $0.3 million, corporate office costs was 8.7% of net revenue for the 2025 Second Quarter. The Company revalued contingent consideration related to certain acquisitions and recognized a net gain (a decrease in the related liabilities) of $0.8 million for the 2025 Second Quarter compared to a net loss (an increase in the related liabilities) of $4.0 million for the 2024 Second Quarter. Operating income was $24.9 million for the 2025 Second Quarter compared to $15.6 million for the 2024 Second Quarter. Excluding the impact of change in value of contingent consideration in the 2025 Second Quarter of $0.8 million, and the 2024 Second Quarter of $4.0 million, operating income increased to $24.1 million for the 2025 Second Quarter from $19.6 million in the 2024 Fourth Quarter. Interest expense increased by $0.4 million to $2.4 million for the 2025 Second Quarter compared to $2.0 million for the 2024 Second Quarter due to a higher average outstanding balance on our revolving credit facility for the 2025 Second Quarter. The interest rate associated with borrowings on the Company's credit facilities was 5.1% for the 2025 Second Quarter and 4.7% for the 2024 Second Quarter, with an all-in-effective interest rate (including all associated costs), of 5.6% and 5.4% over the same periods, respectively. Interest income was less than $0.1 million during the 2025 Second Quarter compared to $1.1 million for the 2024 Second Quarter as the cash on the balance sheet at the end of the 2024 Second Quarter has since been deployed to fund acquisitions. The Company revalued a put-right liability related to the future purchase of an IIP business and recognized a net non-cash expense (an increase in the related liability) of $0.3 million for the 2025 Second Quarter compared to $0.2 million for the 2024 Second Quarter (an increase in the related liability). The provision for income taxes was $4.9 million for the 2025 Second Quarter compared to $3.1 million during the 2024 Second Quarter while the effective tax rate was 28.5% and 29.1% over the same periods, respectively. USPH Net Income and Non-GAAP Measures Net income attributable to non-controlling interest (temporary and permanent) was $5.3 million for the 2025 Second Quarter compared to $4.2 million for the 2024 Second Quarter. USPH Net Income was $12.4 million for the 2025 Second Quarter compared to $7.5 million for the 2024 Second Quarter. In accordance with GAAP, the revaluation of redeemable noncontrolling interest, net of taxes, is not included in net income but is charged directly to retained earnings; however, this change is included in the computation of earnings per share. Earnings per share was $0.58 for the 2025 Second Quarter compared to $0.47 for the 2024 Second Quarter. Non-GAAP Adjusted EBITDA (1) was $26.9 million for the 2025 Second Quarter, an increase of $4.7 million or 21.4%, from $22.1 million for the 2024 Second Quarter. Non-GAAP Operating Results (1) was $12.4 million, or $0.81 per share, for the 2025 Second Quarter compared to $11.0 million, or $0.73 per share, for the 2024 Second Quarter. 2025 Six Months Versus 2024 Six Months Total net revenue for the six months ended June 30, 2025 ('2025 Six Months') increased $58.3 million, or 18.0%, to $381.1 million from $322.9 million for the six months ended June 30, 2024 ('2024 Six Months') while operating costs increased $47.8 million, or 18.4%, to $308.4 million from $260.6 million over the same periods, respectively. Gross profit for the 2025 Six Months was $72.7 million, or 19.1% of net revenue, compared to $62.3 million for the 2024 Six Months, or 19.3% of net revenue. Revenues from physical therapy operations increased $46.8 million, or 16.8% in the 2025 Six Months versus the comparable prior year period due to increased volume from the 51 net new clinics added since the comparable prior year period as well as an increase in net rate per patient visit to $105.49 for 2025 Six Months from $104.23 for 2024 Six Months. Gross profit from physical therapy operations increased $7.9 million, or 14.9%, to $60.7 million for the 2025 Six Months. Excluding certain incentive costs related to the Metro acquisition of $0.3 million, the adjusted gross profit margin was 18.8% for the 2025 Six Months. Revenues from IIP increased $11.5 million, or 25.5%, to $56.4 million for the 2025 Six Months versus the comparable prior year period. Gross profit from IIP operations increased $2.6 million, or 27.3%, to $12.0 million for the 2025 Six Months and the gross profit margin from IIP operations was 21.2% for the 2025 Six Months. Excluding the IIP acquisition made in April 2024, IIP revenue increased by $7.2 million or 16.7% in the 2025 Six Months and gross profit increased $1.9 million or 21.0% in the 2025 Six Months over the comparable prior year period. Corporate office costs were $33.7 million for the 2025 Six Months, compared to $28.3 million for the 2024 Six Months. As a percent of net revenue, corporate office costs were 8.8% for both periods. Excluding the acquisition integration costs and the costs associated with the implementation of the new financial and human resources system of $0.7 million, corporate office costs was 8.7% of net revenue for the 2025 Six Months. The Company revalued contingent consideration related to certain acquisitions and recognized a net gain (a decrease in the related liabilities) of $5.6 million for the 2025 Six Months compared to a net loss of $3.4 million for the 2024 Six Months (an increase in the related liabilities). Operating income was $44.6 million for the 2025 Six Months compared to $30.5 million for the 2024 Six Months. Excluding the impact of change in value of contingent consideration of $5.6 million for the 2025 Six Months and $3.4 million for the 2024 Six Months, operating income increased to $39.0 million for the 2025 Six Months from $33.9 million for the 2024 Six Months, an increase of 14.9%. Other expenses were $4.6 million for the 2025 Six Months compared to $0.9 million for the 2024 Six Months, with the increase primarily due to higher interest expense as a result of increased borrowings and lower interest income as the cash on the balance sheet during the 2024 Six Months has been deployed to fund acquisitions since that time. The provision for income tax was $8.8 million for the 2025 Six Months and $6.2 million for the 2024 Six Months. The effective tax rate was 28.3% and 28.6% over the same periods, respectively. USPH Net Income was $22.3 million for the 2025 Six Months as compared to $15.6 million for the 2024 Six Months while earnings per share was $1.38 for the 2025 Six Months compared to $0.93 for the 2024 Six Months. Non-GAAP Adjusted EBITDA increased $7.5 million to $46.4 million for the 2025 Six Months from $38.9 million for the 2024 Six Months while non-GAAP Operating Results increased $0.9 million to $19.7 million, or $1.30 per share, for the 2025 Six Months from $18.8 million, or $1.25 per share, for the 2024 Six Months. See pages 13 to 15 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure. For additional information on 2025 Six Months results, please refer to the Company's Quarterly Report on Form 10-Q which is expected to be filed with the Securities and Exchange Commission on August 8, 2025. BALANCE SHEET AND CASH FLOW Total cash and cash equivalents were $34.1 million as of June 30, 2025, compared to $41.4 million as of December 31, 2024, and $112.9 million as of June 30, 2024. The Company had $159.5 million in outstanding borrowings and $150.5 million in available credit under the Company's revolving facility as of June 30, 2025. This compares to $151.6 million of outstanding borrowings and $164.0 million in available credit under the Company's revolving facility as of December 31, 2024. RECENT ACQUISITIONS On April 30, 2025, the Company announced the acquisition of an outpatient home-care physical and speech therapy practice through its 50%-owned subsidiary, MSO Metro, LLC. MSO Metro LLC. acquired 80% of equity interests of the practice, with the original practice owners retaining 20% of equity interests. The practice currently generates approximately $2.1 million in annual revenue. On July 31, 2025, the Company acquired a 60% equity interest in a three-clinic practice with the practice owners retaining a 40% equity interest. The business currently generates $5.3 million in annual revenue and 28,000 in annual visits. The Company's strategy is to continue acquiring multi-clinic outpatient physical therapy practices and home-care physical and speech therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships, and to continue acquiring companies that provide industrial injury prevention services. 2025 EARNINGS GUIDANCE Management raised its Adjusted EBITDA guidance for full year 2025 to a range of $93.0 million to $97.0 million based on the Company's strong year-to-date performance and management's confidence in its ability to continue to deliver solid results for its shareholders in the second half of 2025. The annual earnings guidance figures will not be updated unless there is a material development that causes management to believe that Adjusted EBITDA will be significantly outside the given range. QUARTERLY DIVIDEND The Company's Board of Directors declared a quarterly dividend of $0.45 per share payable on September 12, 2025, to shareholders of record on August 22, 2025. SHARE REPURCHASE PROGRAM The Company's Board of Directors approved a share repurchase program effective August 5, 2025. The program authorizes the repurchase by the Company of up to $25 million of its outstanding shares of common stock over the period ending on December 31, 2026. Under the share repurchase program, shares may be repurchased from time to time in the open market or negotiated transactions at prevailing market rates, or by other means in accordance with federal securities laws. The timing and amount of share repurchases under the share repurchase program, if any, will depend on several factors, including the Company's stock price performance, ongoing capital allocation priorities and general market conditions. CONFERENCE CALL INFORMATION U.S. Physical Therapy's management will host a conference call at 10:30 a.m. ET / 9:30 a.m. CT, on August 7, 2025, to discuss the Company's financial results for the three and six months ended June 30, 2025. Interested parties may participate in the call by dialing (800) 343-4136 (Primary) or (203) 518-9843 (Alternate) and conference ID of USPHQ225. Please call approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company's website at at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025, on the Company's website. FORWARD LOOKING STATEMENTS This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as 'believes', 'expects', 'intends', 'plans', 'appear', 'should' and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to: changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status; revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction; changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients; private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability; compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply; compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply ; competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets; the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants; certain of our acquisition agreements contain put-rights related to a future purchase of significant equity interests in our subsidiaries or in a separate company; the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations; our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business; changes as the result of government enacted national healthcare reform; the ability to control variable interest entities for which we do not have a direct ownership; business and regulatory conditions including federal and state regulations; governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs; revenue and earnings expectations; contingent consideration provisions in certain of our acquisition agreements, the value of which may impact future financial results; legal actions, which could subject us to increased operating costs and uninsured liabilities; general economic conditions, including but not limited to inflationary and recessionary periods; actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations; our business depends on hiring, training, and retaining qualified employees; availability and cost of qualified physical therapists; competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line; our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses; impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests); maintaining our information technology systems with adequate safeguards to protect against cyber-attacks; a security breach of our or our third party vendors' information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act; maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected; maintaining adequate internal controls; maintaining necessary insurance coverage; availability, terms, and use of capital; and weather and other seasonal factors. Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 3, 3025 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law. GLOSSARY OF TERMS – REVENUE METRICS Mature clinics are clinics (physical clinic locations and home-care business units) opened or acquired prior to January 1, 2024, and are still operating as of the balance sheet date. Net rate per patient visit is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented. Patient visits is the number of unique patient visits during the periods presented for both physical clinic locations and home-care. Average daily visits per clinic per day is patient visits (excluding home-care visits) divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented. ABOUT U.S. PHYSICAL THERAPY, INC. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 774 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS) June 30, 2025 December 31, 2024 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 34,086 $ 41,362 Patient accounts receivable, less provision for credit losses of $3,928 and $3,506, respectively 65,956 59,040 Accounts receivable - other 27,429 26,626 Other current assets 13,061 10,555 Total current assets 140,532 137,583 Fixed assets: Furniture and equipment 66,756 68,128 Leasehold improvements 55,218 51,105 Fixed assets, gross 121,974 119,233 Less accumulated depreciation and amortization (89,853 ) (87,093 ) Fixed assets, net 32,121 32,140 Operating lease right-of-use assets 137,248 133,936 Investment in unconsolidated affiliate 12,320 12,190 Goodwill 677,595 667,152 Other identifiable intangible assets, net 175,627 179,311 Other assets 4,157 5,155 Total assets $ 1,179,600 $ 1,167,467 Current liabilities: Accounts payable - trade $ 4,200 $ 5,936 Accrued expenses 65,436 59,513 Current portion of operating lease liabilities 41,038 39,835 Current portion of term loan and notes payable 8,168 10,999 Total current liabilities 118,842 116,283 Notes payable, net of current portion 321 903 Revolving facility 24,500 11,000 Term loan, net of current portion and deferred financing costs 127,093 130,627 Deferred taxes 34,402 29,465 Operating lease liabilities, net of current portion 104,279 101,868 Other long-term liabilities 4,571 18,275 Total liabilities 414,008 408,421 Redeemable non-controlling interest - temporary equity 263,298 269,025 Commitments and Contingencies U.S. Physical Therapy, Inc. ("USPH") shareholders' equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - Common stock, $.01 par value, 20,000,000 shares authorized, 17,418,856 and 17,309,120 shares issued, respectively 172 172 Additional paid-in capital 294,636 290,321 Accumulated other comprehensive gain 1,214 2,799 Retained earnings 236,356 227,265 Treasury stock at cost, 2,214,737 shares (31,628 ) (31,628 ) Total USPH shareholders' equity 500,750 488,929 Non-controlling interest - permanent equity 1,544 1,092 Total USPH shareholders' equity and non-controlling interest - permanent equity 502,294 490,021 Total liabilities, redeemable non-controlling interest, USPH shareholders' equity and non-controlling interest - permanent equity $ 1,179,600 $ 1,167,467 Expand U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS) Six Months Ended June 30, 2025 June 30, 2024 OPERATING ACTIVITIES Net income including non-controlling interest $ 31,188 $ 23,329 Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities: Depreciation and amortization 11,924 8,609 Provision for credit losses 3,843 3,344 Equity-based awards compensation expense 3,888 3,916 Amortization of debt issue costs 210 210 Change in deferred income taxes 7,279 770 Change in revaluation of put-right liability 743 303 Change in fair value of contingent earn-out consideration (5,612 ) 3,434 Equity of earnings in unconsolidated affiliate (794 ) (519 ) Loss on sale of fixed assets 438 51 Loss on sale of a partnership 123 - Changes in operating assets and liabilities: Patient accounts receivable, net (10,232 ) (5,110 ) Accounts receivable - other 355 (2,351 ) Other current and long term assets (4,426 ) (1,642 ) Accounts payable and accrued expenses (7,914 ) (1,481 ) Other long-term liabilities (827 ) 548 Net cash provided by operating activities 30,186 33,411 INVESTING ACTIVITIES Purchase of fixed assets (5,830 ) (4,174 ) Purchase of majority interest in businesses, net of cash acquired (6,890 ) (38,695 ) Purchase of redeemable non-controlling interest, temporary equity (8,427 ) (6,230 ) Purchase of non-controlling interest, permanent equity (149 ) (527 ) Proceeds from the sale of non-controlling interest, permanent equity 9 26 Proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity 15 69 Repayment of notes receivable related to redeemable non-controlling interest 346 375 Proceeds from the sale of partnership 700 - Distributions from unconsolidated affiliate 664 532 Other 228 (131 ) Net cash (used in) investing activities (19,334 ) (48,755 ) FINANCING ACTIVITIES Proceeds from revolving facility 73,500 - Payments on revolving facility (60,000 ) - Distributions to non-controlling interest, permanent and temporary equity (10,697 ) (8,318 ) Cash dividends paid to shareholders (13,678 ) (13,264 ) Payments on term loan (5,625 ) (1,875 ) Principal payments on notes payable (1,628 ) (1,113 ) Net cash (used in) financing activities (18,128 ) (24,570 ) Net (decrease) in cash and cash equivalents (7,276 ) (39,914 ) Cash and cash equivalents - beginning of period 41,362 152,825 Cash and cash equivalents - end of period $ 34,086 $ 112,911 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 9,833 $ 4,932 Interest paid 4,683 3,708 Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion - 955 Fair market value of initial contingent consideration related to purchase of businesses 3,059 2,800 Offset of notes receivable associated with purchase of redeemable non-controlling interest 254 75 Notes payable related to purchase of non-controlling interest, temporary equity - 22 Notes payable related to purchase of redeemable non-controlling interest, temporary equity 89 - Notes receivable related to sale of redeemable non-controlling interest, temporary equity 660 402 Notes receivable related to the sale of non-controlling interest, permanent equity 29 243 Expand U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES ADJUSTED EBITDA AND OPERATING RESULTS The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results. The tables also provide a reconciliation of additional non-GAAP measures to the most comparable GAAP measure. Management believes providing Adjusted EBITDA and Operating Results to investors is useful for comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. Management uses Adjusted EBITDA and Operating Results, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period. Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs, costs related to a one-time financial and human resources systems upgrade, loss on sale of a partnership and other income and related portions for non-controlling interests. Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less, changes in revaluation of a put-right liability, clinic closure costs, loss on sale of a partnership, changes in fair value of contingent earn-out consideration, business acquisition related costs, costs related to a one-time financial and human resources systems upgrade and any allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact. Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA, Operating Results and other non-GAAP measures should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements. U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES Adjusted EBITDA (a non-GAAP measure) Net income attributable to USPH shareholders $ 12,393 $ 7,506 $ 22,292 $ 15,552 Adjustments: Provision for income taxes 4,933 3,083 8,793 6,222 Depreciation and amortization 6,057 4,514 11,924 8,609 Interest expense, debt and other, net 2,422 1,980 4,701 3,948 Equity-based awards compensation expense 2,117 1,919 3,888 3,916 Interest income from investments (28 ) (1,074 ) (52 ) (2,617 ) Change in revaluation of put-right liability 339 223 743 303 (Gain) loss on change in fair value of contingent earn-out consideration (790 ) 4,046 (5,612 ) 3,434 Clinic Closure costs (1) 69 551 311 677 Business acquisition related costs (2) 320 - 800 - ERP implementation costs (3) 159 - 221 - Loss on sale of a partnership - - 123 - Other income (47 ) (109 ) (122 ) (171 ) Allocation to non-controlling interests (1,081 ) (515 ) (1,608 ) (978 ) $ 26,863 $ 22,124 $ 46,402 $ 38,895 Operating Results (a non-GAAP measure) Net income attributable to USPH shareholders $ 12,393 $ 7,506 $ 22,292 $ 15,552 Adjustments: Gain (loss) on change in fair value of contingent earn-out consideration (790 ) 4,046 (5,612 ) 3,434 Change in revaluation of put-right liability 339 223 743 303 Clinic closure costs (1) 69 551 311 677 Business acquisition related costs (2) 320 - 800 - ERP implementation costs (3) 159 - 221 - Loss on sale of a partnership - - 123 - Allocation to non-controlling interests (156 ) (68 ) (118 ) (84 ) Tax effect at statutory rate (federal and state) 16 (1,214 ) 903 (1,106 ) $ 12,350 $ 11,044 $ 19,663 $ 18,776 Operating Results per share (a non-GAAP measure) $ 0.81 $ 0.73 $ 1.30 $ 1.25 Earnings per share Computation of earnings per share - USPH shareholders: Net income attributable to USPH shareholders $ 12,393 $ 7,506 $ 22,292 $ 15,552 Charges to retained earnings: Revaluation of redeemable non-controlling interest (4,806 ) (622 ) (1,903 ) (2,061 ) Tax effect at statutory rate (federal and state) 1,228 159 486 527 $ 8,815 $ 7,043 $ 20,875 $ 14,018 Earnings per share (basic and diluted) $ 0.58 $ 0.47 $ 1.38 $ 0.93 Shares used in computation - basic and diluted 15,197 15,072 15,165 15,044 Expand _______________________ (1) Costs associated with the closure of three clinics in the 2025 Second Quarter, 10 clinics during the 2025 Six Months, five clinics in the 2024 Second Quarter and 11 clinics in the 2024 Six Months. (2) Primarily consists of retention bonuses and legal and consulting expenses related to the acquisitions of equity interests in certain partnerships. (3) Consists of costs related to a one-time financial and human resources systems upgrade. Expand U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP MEASURES TO THE MOST COMPARABLE GAAP MEASURES (IN THOUSANDS, EXCEPT PER SHARE DATA AND PERCENTAGES) The tables below reconcile other non-GAAP measures to the most directly comparable GAAP measures for the 2025 Second Quarter and the 2025 Six Months. No commensurate adjustments were made in the comparable prior year period. _______________________ (1) Certain incentive costs related to the Metro acquisition. We believe that presenting this information will allow investors to evaluate the performance of the Company's business more objectively. (2) Excludes costs related to management contracts. * Not meaningful Expand U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES Revenue Metrics Number of Clinics (2) Net Rate Per Patient Visit (1) Patient Visits (1) Average Visits Per Clinic Per Day (3) 2025 2024 2025 2024 2025 2024 2025 2024 First quarter 729 679 $ 105.66 $ 103.37 1,443,805 1,268,002 31.2 29.5 Second quarter 732 681 $ 105.33 $ 105.05 1,558,756 1,335,335 32.7 30.6 Third quarter 661 $ 105.65 1,317,051 30.1 Fourth quarter 722 $ 104.73 1,432,801 31.6 Year-to-date 722 $ 104.71 3,002,561 5,353,189 30.4 Expand _______________________ (1) See definition of the metrics above in the Glossary of Terms – Revenue Metrics section on page 7. (2) The Company also manages clinics owned by third parties through management contracts. In addition to the clinic count shown above (excluding the home-care business unit count), as of June 30, 2025, the Company managed 36 clinics bringing the total owned/managed clinics to 768. In comparison, as of June 30, 2024, the Company managed 41 clinics bringing the total owned/managed clinics to 722. (3) Excludes home-care visits. Expand Clinic Count Roll Forward (1) 2025 2024 Owned Managed Total Owned Managed Total Number of clinics, beginning of period 722 39 761 671 43 714 Q1 additions 14 - 14 14 - 14 Q1 closed or sold (7 ) (2 ) (9 ) (6 ) (2 ) (8 ) Number of clinics, end of period 729 37 766 679 41 720 Q2 additions 6 - 6 7 - 7 Q2 closed or sold (3 ) (1 ) (4 ) (5 ) - (5 ) Number of clinics, end of period 732 36 768 681 41 722 Q3 additions 12 - 12 Q3 closed or sold (32 ) (2 ) (34 ) Number of clinics, end of period 661 39 700 Q4 additions 63 - 63 Q4 closed or sold (2 ) - (2 ) Number of clinics, end of period 722 39 761 Year-to-date total additions 20 - 20 96 - 96 Year-to-date total closed or sold (10 ) (3 ) (13 ) (45 ) (4 ) (49 ) _______________________ (1) Excludes the home-care business. Expand

Innovative Industrial Properties Reports Second Quarter 2025 Results
Innovative Industrial Properties Reports Second Quarter 2025 Results

Business Wire

time7 minutes ago

  • Business Wire

Innovative Industrial Properties Reports Second Quarter 2025 Results

SAN DIEGO--(BUSINESS WIRE)--Innovative Industrial Properties, Inc. (NYSE: IIPR) ("IIP" or the "Company"), the first and only real estate company on the New York Stock Exchange focused on the regulated U.S. cannabis industry, announced today results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Financial Results and Dividend Generated total revenues of $62.9 million and net income attributable to common stockholders of $25.1 million, or $0.86 per share (all per share amounts in this press release are reported on a diluted basis unless otherwise noted). Recorded adjusted funds from operations ("AFFO") and normalized funds from operations ("Normalized FFO") of $48.4 million and $44.1 million, respectively. Paid a quarterly dividend of $1.90 per common share on July 15, 2025 to stockholders of record as of June 30, 2025. Since its inception, IIP has paid $1.0 billion in common stock dividends to its stockholders. __________________________________________________________________ Definitions of the above-mentioned non-GAAP financial measures, together with reconciliations to net income (loss) in accordance with GAAP, appear at the end of this release. Expand Portfolio Update - General In April, leased 205,000 square feet to Berry Green at IIP's property in Warren, Michigan. In April, sold a property in Michigan for $9.0 million (excluding transaction costs) and provided an interest only, secured loan for $8.5 million to the buyer of the property. The Company also received a $1.0 million loan origination fee in connection with the transaction. In June, sold a property in Palm Springs, California for $1.8 million in net proceeds. Portfolio Update - Lease Defaults In March 2025, the Company launched a strategic initiative aimed at improving long-term financial performance by replacing certain underperforming tenants with more financially stable, long-term operators. As part of this effort, it declared several tenants, including 4Front Ventures, Gold Flora, and TILT Holdings, in default for nonpayment of rent and is pursuing its legal rights, which may include evictions. Additionally, PharmaCann previously defaulted on its eleven leases with the Company across multiple states where the Company has commenced legal proceedings to regain possession of the properties they continue to occupy and re-leased one property located in Warren, Michigan to Berry Green. The Company is actively working to recover amounts due from these tenants and to re-lease vacated properties. Balance Sheet Highlights (at June 30, 2025) 11% debt to total gross assets, with $2.6 billion in total gross assets Total liquidity was $192.4 million as of June 30, 2025, consisting of cash and cash equivalents and short-term investments (each as reported in IIP's consolidated balance sheet as of June 30, 2025) and availability under IIP's revolving credit facility. Debt service coverage ratio of 15.0x (calculated in accordance with IIP's 5.50% Unsecured Senior Notes due 2026). Financing Activity Issued 173,834 shares of Series A Preferred Stock under IIP's 'at-the-market' equity offering program for $4.0 million in net proceeds. Repurchased 366,952 shares of common stock under the Company's share repurchase program for $19.8 million at a weighted average price of $53.98 per share under the Company's $100 million share repurchase program, which expires March 2026. As of June 30, 2025, the Company had $79.9 million in common stock repurchases remaining available under the share repurchase program. Property Portfolio Statistics (as of June 30, 2025) Total property portfolio comprises 108 properties across 19 states, with 9.0 million rentable square feet "RSF" (including 588,000 RSF under development / redevelopment), consisting of: Operating portfolio: 105 properties, representing 8.5 million RSF. Under development / redevelopment portfolio consists of three properties expected to comprise 491,000 RSF at completion and is as follows: 236,000 square feet located at 63795 19th Avenue in Palm Springs, California (pre-leased) 192,000 square feet located at Inland Center Drive in San Bernardino, California 12-acre development site located at Leah Avenue in San Marcos, Texas Financial Results For the three months ended June 30, 2025, IIP generated total revenues of $62.9 million, compared to $79.8 million for the same period in 2024, a decrease of 21%. The decrease was primarily driven by tenant defaults totaling $15.8 million related to properties leased to PharmaCann, Gold Flora, TILT and 4Front. In addition, there was a decrease of $1.3 million related to properties vacated or sold, a $3.9 million decrease from a one-time disposition-contingent lease termination fee that was collected during the three months ended June 30, 2024 in connection with the sale of our property in California, and a $0.6 million decrease in tenant reimbursement revenue primarily due to tenant defaults. These decreases were partially offset by a $1.6 million increase from the two properties acquired in 2024 and one property acquired in 2025, a $1.5 million increase from new leases on five existing properties, and a $1.6 million increase from annual contractual rent escalations. For the three months ended June 30, 2025, IIP applied $18,000 of security deposits for payment of rent on one property leased to Emerald Growth, which was sold during the second quarter. For the three months ended June 30, 2024, IIP applied $0.6 million of security deposits for payment of rent on properties leased to two tenants. Dividend On June 13, 2025, the Board of Directors declared a second quarter 2025 dividend of $1.90 per common share, representing an annualized dividend of $7.60 per common share. The dividend was paid on July 15, 2025 to stockholders of record as of June 30, 2025. Supplemental Information Supplemental financial information is available in the Investor Relations section of IIP's website at Teleconference and Webcast Innovative Industrial Properties, Inc. will conduct a conference call and webcast at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) on Thursday, August 7, 2025 to discuss IIP's financial results and operations for the second quarter ended June 30, 2025. The call will be open to all interested investors through a live audio webcast at the Investor Relations section of IIP's website at or live by calling 1-877-328-5514 (domestic) or 1-412-902-6764 (international) and asking to be joined to the Innovative Industrial Properties, Inc. conference call. The complete webcast will be archived for 90 days on IIP's website. A telephone playback of the conference call will also be available from 12:00 p.m. Pacific Time on Thursday, August 7, 2025 until 12:00 p.m. Pacific Time on Thursday, August 14, 2025, by calling 1-877-344-7529 (domestic), 855-669-9658 (Canada) or 1-412-317-0088 (international) and using access code 9556330. About Innovative Industrial Properties Innovative Industrial Properties, Inc. is a real estate investment trust (REIT) focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated cannabis facilities. Additional information is available at This press release contains statements that IIP believes to be 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts are forward-looking statements. When used in this press release, words such as IIP 'expects,' 'intends,' 'plans,' 'estimates,' 'anticipates,' 'believes' or 'should' or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could materially affect actual results, performances or achievements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risk factors discussed in the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's subsequent reports filed with the Securities and Exchange Commission. Accordingly, there is no assurance that the Company's expectations will be realized. IIP disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws. INNOVATIVE INDUSTRIAL PROPERTIES, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share and per share amounts) June 30, Assets 2025 2024 Real estate, at cost: Land $ 146,469 $ 146,772 Buildings and improvements 2,249,408 2,230,807 Construction in progress 57,487 62,393 Total real estate, at cost 2,453,364 2,439,972 Less accumulated depreciation (306,594 ) (271,190 ) Net real estate held for investment 2,146,770 2,168,782 Construction loan receivable 22,800 22,800 Cash and cash equivalents 99,666 146,245 Investments 5,258 5,000 Right of use office lease asset 731 946 In-place lease intangible assets, net 6,955 7,385 Other assets, net 22,875 26,889 Total assets $ 2,305,055 $ 2,378,047 Liabilities and stockholders' equity Liabilities: Notes due 2026, net $ 289,861 $ 297,865 Building improvements and construction funding payable 5,647 10,230 Accounts payable and accrued expenses 10,183 10,561 Dividends payable 54,661 54,817 Rent received in advance and tenant security deposits 51,647 57,176 Other liabilities 12,650 11,338 Total liabilities 424,649 441,987 Commitments and contingencies Stockholders' equity: Preferred stock, par value $0.001 per share, 50,000,000 shares authorized: 9.00% Series A cumulative redeemable preferred stock, liquidation preference of $25.00 per share, 1,561,654 and 1,002,673 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 36,843 23,632 Common stock, par value $0.001 per share, 50,000,000 shares authorized: 28,017,520 and 28,331,833 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 28 28 Additional paid-in capital 2,107,963 2,124,113 Dividends in excess of earnings (264,428 ) (211,713 ) Total stockholders' equity 1,880,406 1,936,060 Total liabilities and stockholders' equity $ 2,305,055 $ 2,378,047 Expand INNOVATIVE INDUSTRIAL PROPERTIES, INC. CONSOLIDATED STATEMENTS OF INCOME For the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) (In thousands, except share and per share amounts) 2025 2024 2025 2024 Revenues: Rental (including tenant reimbursements) $ 62,866 $ 79,253 $ 134,563 $ 154,167 Other 25 540 50 1,080 Total revenues 62,891 79,793 134,613 155,247 Expenses: Property expenses 6,867 6,863 14,246 13,572 General and administrative expense 8,626 9,661 17,087 19,223 Depreciation and amortization expense 18,500 17,473 36,891 34,623 Impairment loss on real estate — — 3,527 — Total expenses 33,993 33,997 71,751 67,418 Gain (loss) on sale of real estate — (3,449 ) — (3,449 ) Income from operations 28,898 42,347 62,862 84,380 Interest income 1,570 3,966 3,183 5,750 Interest expense (4,444 ) (4,320 ) (8,944 ) (8,709 ) Net income 26,024 41,993 57,101 81,421 Preferred stock dividends (878 ) (338 ) (1,659 ) (676 ) Net income attributable to common stockholders $ 25,146 $ 41,655 $ 55,442 $ 80,745 Net income attributable to common stockholders per share Basic $ 0.87 $ 1.45 $ 1.92 $ 2.82 Diluted $ 0.86 $ 1.44 $ 1.90 $ 2.79 Weighted-average shares outstanding: Basic 27,924,092 28,250,843 28,098,850 28,197,930 Expand INNOVATIVE INDUSTRIAL PROPERTIES, INC. FFO, NORMALIZED FFO AND AFFO For the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) (In thousands, except share and per share amounts) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Net income attributable to common stockholders $ 25,146 $ 41,655 $ 55,442 $ 80,745 Real estate depreciation and amortization 18,500 17,473 36,891 34,623 Impairment loss on real estate — — 3,527 — Disposition-contingent lease termination fee, net of loss on sale of real estate (1) — (451 ) — (451 ) FFO attributable to common stockholders (basic) 43,646 58,677 95,860 114,917 Cash and non-cash interest expense on Exchangeable Senior Notes — — — 28 FFO attributable to common stockholders (diluted) 43,646 58,677 95,860 114,945 Litigation-related expense 413 164 819 310 Loss (gain) on partial repayment of Notes due 2026 — — (32 ) — Normalized FFO attributable to common stockholders (diluted) 44,059 58,841 96,647 115,255 Income on seller-financed notes (2) 1,164 403 1,317 806 Deferred lease payments received on sales-type leases (3) 5 1,462 25 2,918 Stock-based compensation 2,672 4,371 4,750 8,686 Non-cash interest expense 476 401 946 789 Above-market lease amortization 23 23 46 46 AFFO attributable to common stockholders (diluted) $ 48,399 $ 65,501 $ 103,731 $ 128,500 FFO per common share – diluted $ 1.54 $ 2.06 $ 3.37 $ 4.03 Normalized FFO per common share – diluted $ 1.56 $ 2.06 $ 3.40 $ 4.04 AFFO per common share – diluted $ 1.71 $ 2.29 $ 3.65 $ 4.50 Weighted average common shares outstanding – basic 27,924,092 28,250,843 28,098,850 28,197,930 Restricted stock and RSUs 393,601 300,582 353,261 289,736 PSUs — 20,713 — 20,713 Dilutive effect of Exchangeable Senior Notes — — — 19,040 Weighted average common shares outstanding – diluted 28,317,693 28,572,138 28,452,111 28,527,419 Expand __________________________________________________________________ (1) Amount reflects the $3.9 million disposition-contingent lease termination fee received concurrently with the sale of IIP's property in Los Angeles, California, net of the loss on sale of the property of $3.4 million. (2) Amount reflects the non-refundable cash payments received on the two seller-financed notes issued to IIP by the buyers in connection with IIP's disposition of certain properties which are recognized as a deposit liability and is included in other liabilities in IIP's consolidated balance sheet as of June 30, 2025, as the transactions did not qualify for recognition as completed sales. (3) Amount reflects the non-refundable lease payments received on two sales-type leases which are recognized as a deposit liability starting on January 1, 2024, and is included in other liabilities in IIP's consolidated balance sheet as of June 30, 2025, as the transactions did not qualify for recognition as completed sales. Prior to the lease modifications on January 1, 2024, which extended the initial lease terms, the leases were classified as operating leases and the lease payments received were recognized as rental revenue and therefore, included in net income attributable to common stockholders. Expand FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts, Inc. (NAREIT). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT's operating performance equal to net income, computed in accordance with accounting principles generally accepted in the United States (GAAP), excluding gains (or losses) from sales of property, depreciation, amortization and impairment related to real estate properties, and after adjustments for unconsolidated partnerships and joint ventures. IIP also excludes from FFO any disposition-contingent lease termination fee received in connection with a property sale. Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management believes FFO and FFO per share to be supplemental measures of a REIT's performance because they provide an understanding of the operating performance of IIP's properties without giving effect to certain significant non-cash items, primarily depreciation expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. IIP believes that by excluding the effect of depreciation, FFO and FFO per share can facilitate comparisons of operating performance between periods. IIP reports FFO and FFO per share because these measures are observed by management to also be the predominant measures used by the REIT industry and industry analysts to evaluate REITs and because FFO per share is consistently reported, discussed, and compared by research analysts in their notes and publications about REITs. For these reasons, management has deemed it appropriate to disclose and discuss FFO and FFO per share. IIP computes Normalized FFO by adjusting FFO to exclude certain GAAP income and expense amounts that management believes are infrequent and unusual in nature and/or not related to IIP's core real estate operations. Exclusion of these items from similar FFO-type metrics is common within the equity REIT industry, and management believes that presentation of Normalized FFO and Normalized FFO per share provides investors with a metric to assist in their evaluation of IIP's operating performance across multiple periods and in comparison to the operating performance of other companies, because it removes the effect of unusual items that are not expected to impact IIP's operating performance on an ongoing basis. Normalized FFO is used by management in evaluating the performance of its core business operations. Items included in calculating FFO that may be excluded in calculating Normalized FFO include certain transaction-related gains, losses, income or expense or other non-core amounts as they occur. Management believes that AFFO and AFFO per share are also appropriate supplemental measures of a REIT's operating performance. IIP calculates AFFO by adjusting Normalized FFO for certain cash and non-cash items. For the six months ended June 30, 2024, FFO (diluted), Normalized FFO and AFFO, and FFO, Normalized FFO and AFFO per diluted share include the dilutive impact of the assumed full exchange of the Exchangeable Senior Notes for shares of common stock as of the Exchangeable Senior Notes were exchanged at the beginning of the respective reporting period. The Exchangeable Senior Notes matured in February 2024. For the three and six months ended June 30, 2024, the performance share units ('PSUs') granted to certain employees were included in dilutive securities to the extent the performance thresholds for vesting of the PSUs were met as measured as of June 30, 2024. The PSUs expired on December 31, 2024. IIP's computation of FFO, Normalized FFO and AFFO may differ from the methodology for calculating FFO, Normalized FFO and AFFO utilized by other equity REITs and, accordingly, may not be comparable to such REITs. Further, FFO, Normalized FFO and AFFO do not represent cash flow available for management's discretionary use. FFO, Normalized FFO and AFFO should not be considered as an alternative to net income (computed in accordance with GAAP) as an indicator of IIP's financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of IIP's liquidity, nor is it indicative of funds available to fund IIP's cash needs, including IIP's ability to pay dividends or make distributions. FFO, Normalized FFO and AFFO should be considered only as supplements to net income computed in accordance with GAAP as measures of IIP's operations.

Sila Realty Trust Announces Second Quarter 2025 Results
Sila Realty Trust Announces Second Quarter 2025 Results

Business Wire

time7 minutes ago

  • Business Wire

Sila Realty Trust Announces Second Quarter 2025 Results

TAMPA, Fla.--(BUSINESS WIRE)--Sila Realty Trust, Inc. (NYSE: SILA) ('Sila', the 'Company', 'we', or 'us'), a net lease real estate investment trust ('REIT') with a strategic focus on investing in the growing and resilient healthcare sector, today announced operating results for the second quarter ended June 30, 2025. Highlights for the quarter ended June 30, 2025: Net income of $8.6 million, or $0.15 per diluted share Cash net operating income*, or Cash NOI, of $41.9 million Adjusted funds from operations*, or AFFO, of $30.0 million, or $0.54 per diluted share Declared and paid cash distributions per share of $0.40 for the quarter Acquired an inpatient rehabilitation facility for $24.1 million in Dover, Delaware Subsequent Events On August 5, 2025, the Company's board of directors, or the Board, authorized a quarterly cash dividend of $0.40 per share of common stock payable on September 4, 2025, to the Company's stockholders of record as of the close of business on August 21, 2025 Acquired two medical outpatient buildings for $16.2 million in Southlake, Texas On August 4, 2025, the Board authorized a share repurchase program of up to $75.0 million in gross purchase proceeds for a period of three-years from August 4, 2025, subject to the limitation of $25.0 million in gross purchase proceeds in any twelve-month period Management Commentary "Continuing our disciplined and strategic approach to investing through the first six months of 2025, we allocated capital toward growing Sila's portfolio of high quality, net-lease healthcare properties and purchasing outstanding shares at a price that we believe to be a significant discount to the intrinsic value of the Company," stated Michael A. Seton, President and Chief Executive Officer of the Company. "We realized cash NOI growth this quarter when compared to both the preceding quarter and the prior year's same quarter, and positive leasing spreads on all leases renewed during the quarter. Despite headline news surrounding the U.S. economic and legislative landscape, our focus on necessity-based healthcare solutions, partnering with operators that deliver better outcomes for patients in convenient locations, and our triple-net lease structures, allows us to remain optimistic in our ability to continue our success going forward." *Some of the financial measures throughout this press release are non-GAAP measures. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and reconciliations to the most directly comparable GAAP measure. Financial Results Net Income Our GAAP net income for the second quarter of 2025 was $8.6 million, or $0.15 per diluted share, compared to $4.6 million, or $0.08 per diluted share, for the second quarter of 2024. Our GAAP net income for the first half of 2025 was $16.5 million, or $0.30 per diluted share, compared to $19.6 million, or $0.34 per diluted share for the first half of 2024. Cash NOI Cash NOI was $41.9 million for the second quarter of 2025, as compared to $39.9 million for the second quarter of 2024. The increase in Cash NOI is primarily the result of acquisitions and second quarter 2025 Cash NOI increases at our same store properties compared to the second quarter of 2024, primarily as a result of contractual rent increases. This increase was partially offset by the vacancy of the Stoughton Healthcare Facility as a result of the Steward Healthcare bankruptcy. Cash NOI was $83.1 million for the first half of 2025, as compared to $86.8 million for the first half of 2024. The decrease in Cash NOI is primarily due to the receipt of a lease termination fee and the severance fee received from GenesisCare USA, Inc. and its affiliates in the first quarter of 2024, the vacancy of the Stoughton Healthcare Facility as a result of the Steward Healthcare bankruptcy, and property dispositions. This decrease was partially offset by acquisitions and Cash NOI increases at our other same store properties in the first half of 2025, compared to the first half of 2024, primarily as a result of contractual rent increases. AFFO AFFO was $30.0 million, or $0.54 per diluted share, during the second quarter of 2025, compared to $30.8 million, or 0.54 per diluted share, during the second quarter of 2024. AFFO for the first half of 2025 was $59.4 million, or $1.07 per diluted share, compared to $69.1 million, or $1.20 per diluted share, for the first half of 2024. Real Estate Portfolio Highlights Investment Activity During the quarter ended June 30, 2025, the Company acquired one healthcare property in Dover, Delaware, comprising 42,140 rentable square feet, for a purchase price of $24.1 million. The property is 100% leased under an absolute-net lease to a joint venture between Bayhealth and PAM Health with a lease expiration in 2036. Portfolio As of June 30, 2025, Sila's well diversified real estate portfolio consisted of 136 properties comprising approximately 5.2 million rentable square feet. The weighted average remaining lease term was approximately 9.5 years with 22.1% of annualized base rent maturing in the next five years and a weighted average fixed rent escalation rate of 2.2%, excluding leases tied to the consumer price index. As of June 30, 2025, the percentage of rentable square feet leased was 99.2%. There was a 3.2 percentage point increase in the percentage of square feet leased in the second quarter of 2025. This increase was largely attributable to taking the Stoughton Healthcare Facility out of service during the second quarter. Balance Sheet and Capital Markets Activities Sila had a strong balance sheet and liquidity position totaling approximately $568.8 million, consisting of $24.8 million in cash and cash equivalents and $544.0 million of availability under its unsecured credit facility as of June 30, 2025. Total principal debt outstanding under the unsecured credit facility as of June 30, 2025, was $581.0 million. Of the $581.0 million, $525.0 million was fixed through 10 interest rate swap agreements. As of June 30, 2025, the Company's weighted average interest rate on the total principal debt outstanding was 4.7%, including the impact of the interest rate swap agreements. As of June 30, 2025, net debt to enterprise value was approximately 29.8%. On August 4, 2025, the Board authorized a share repurchase program of up to $75.0 million in gross purchase proceeds for a period of three-years from August 4, 2025, subject to the limitation of $25.0 million in gross purchase proceeds in any twelve-month period. Repurchases of common stock under the share repurchase program may be made from time to time in the open market, in privately negotiated purchases, in accelerated share repurchase programs or by any other lawful means. The number of shares of common stock purchased and the timing of any purchases will depend on a number of factors, including the price and availability of common stock and general market conditions. The three-year share repurchase program replaces the prior one-year share repurchase program authorized on August 16, 2024, which allowed for the repurchase of up to the lesser of 1.5 million shares of the Company's outstanding common stock or $25.0 million in gross purchase proceeds. Distributions The Company's dividend payout to AFFO ratio was 74.0% for the quarter ended June 30, 2025. On August 5, 2025, the Board approved and authorized a quarterly cash dividend of $0.40 per share of Common Stock payable on September 4, 2025, to the Company's stockholders of record as of the close of business on August 21, 2025. The quarterly cash dividend of $0.40 per share represents an annualized amount of $1.60 per share. Conference Call and Webcast A conference call and audio webcast for investors and analysts will be held on Thursday, August 7, 2025, at 11:00 a.m. Eastern Time to discuss our second quarter 2025 operating results and to answer questions. The live and archived webcast can be accessed on the "Events" page of the Company's website at or by direct link at The archived webcast will be available for 12 months following the call. About Sila Realty Trust, Inc. Sila Realty Trust, Inc., headquartered in Tampa, Florida, is a net lease real estate investment trust with a strategic focus on investing in the growing and resilient healthcare sector. The Company invests in high quality healthcare facilities along the continuum of care in the pursuit of generating predictable, durable, and growing income streams. Sila's portfolio comprises high quality tenants in geographically diverse facilities, which are positioned to capitalize on the dynamic delivery of healthcare to patients. As of June 30, 2025, the Company owned 136 real estate properties, two undeveloped land parcels and one property taken out of service, located in 67 markets across the United States. For more information, please visit the Company's website at Forward-Looking Statements Certain statements contained herein, other than historical fact, may be considered 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provided by the same. These statements are based on management's current expectations and beliefs and are subject to a number of trends and uncertainties. No forward-looking statement is intended to, nor shall it, serve as a guarantee of future performance. You can identify the forward-looking statements by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'predict,' 'project,' 'seek,' 'should,' 'will' and other similar terms and phrases, including statements about and references to our commitment to investing in necessity, purpose-built healthcare real estate; our strategic focus on lower cost patient settings which support the delivery of specialized care in growing markets; predictions on the durability of our cash flow and financial position; and our ability to continue executing our growth strategy. Forward-looking statements are subject to various risks and uncertainties and factors that could cause actual results to differ materially from the Company's expectations, and you should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and could materially affect the Company's results of operations, financial condition, cash flows, performance or future achievements or events. Additional factors include those described under the section entitled Item 1A. "Risk Factors" of Part I of the Company's 2024 Annual Report on Form 10-K, as filed with the SEC on March 3, 2025, a copy of which is available at The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Supplemental Information The Company routinely provides information for investors and the marketplace through press releases, SEC filings, public conference calls, and the Company's website at The information that the Company posts to its website may be deemed material. Accordingly, the Company encourages investors and others interested in the Company to routinely monitor and review the information that the Company posts on its website, in addition to following the Company's press releases, public conference calls and SEC filings. A glossary of definitions (including those of certain non-GAAP financial measures) and other supplemental information may be found attached as Exhibit 99.2 to the Current Report on Form 8-K filed on August 6, 2025. Non-GAAP Financial Measures This press release includes certain financial performance measures not defined by United States generally accepted accounting principles, or GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in this press release. We believe such measures provide investors with additional information concerning our operating performance and a basis to compare our performance with the performance of other REITs. Our definitions and calculations of these non-GAAP measures may not be the same as similar measures reported by other REITs. These non-GAAP financial measures should not be considered as alternatives to net income attributable to common stockholders (determined in accordance with GAAP) as indicators of our financial performance, as alternatives to cash flows from operating activities (determined in accordance with GAAP), or as measures of our liquidity, nor are these measures necessarily indicative of sufficient cash flows to fund all of our needs. Condensed Consolidated Statements of Comprehensive Income (amounts in thousands, except share data and per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue: Rental revenue $ 48,544 $ 43,554 $ 96,800 $ 94,193 Real estate related notes receivable interest income 188 — 188 — Total revenues 48,732 43,554 96,988 94,193 Expenses: Rental expenses 5,991 5,849 12,317 11,403 Listing-related expenses — 2,924 — 2,980 General and administrative expenses 5,129 5,347 10,827 13,521 Depreciation and amortization 18,182 20,246 35,944 39,144 Impairment losses 3,261 418 6,792 418 Total operating expenses 32,563 34,784 65,880 67,466 Other income (expense): Gain on dispositions of real estate — — — 76 Interest and other income 265 1,051 720 3,292 Interest expense (7,829 ) (5,193 ) (15,154 ) (10,487 ) Increase in current expected credit loss reserve (7 ) — (178 ) — Total other expense (7,571 ) (4,142 ) (14,612 ) (7,119 ) Net income attributable to common stockholders $ 8,598 $ 4,628 $ 16,496 $ 19,608 Other comprehensive (loss) income - unrealized (loss) gain on interest rate swaps, net (4,065 ) (2,115 ) (11,203 ) 753 Comprehensive income attributable to common stockholders $ 4,533 $ 2,513 $ 5,293 $ 20,361 Weighted average number of common shares outstanding: Basic 55,144,522 57,230,472 55,137,632 57,171,756 Diluted 55,715,244 57,601,204 55,722,581 57,574,634 Net income per common share attributable to common stockholders: Basic $ 0.16 $ 0.08 $ 0.30 $ 0.34 Diluted $ 0.15 $ 0.08 $ 0.30 $ 0.34 Expand Non-GAAP Financial Measures Reconciliation A description of FFO, Core FFO and AFFO, and reconciliations of these non-GAAP measures to net income, the most directly comparable GAAP measure, and a description of same store cash NOI and reconciliation of this non-GAAP measure to rental revenue, the most directly comparable GAAP measure, are provided below. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income attributable to common stockholders (1) $ 8,598 $ 4,628 $ 16,496 $ 19,608 Adjustments: Depreciation and amortization of real estate assets 18,155 20,222 35,892 39,097 Gain on dispositions of real estate — — — (76 ) Impairment losses 3,261 418 6,792 418 FFO (1) $ 30,014 $ 25,268 $ 59,180 $ 59,047 Adjustments: Listing-related expenses — 2,924 — 2,980 Severance 11 — 22 1,863 Write-off of straight-line rent receivables related to prior periods 33 — 36 — Accelerated stock-based compensation 19 — 19 863 Amortization of above (below) market lease intangibles, including ground leases, net 22 1,877 45 1,248 Loss on extinguishment of debt — — 233 228 Increase in current expected credit loss reserve 7 — 178 — Core FFO (1) $ 30,106 $ 30,069 $ 59,713 $ 66,229 Adjustments: Deferred rent (2) 322 333 641 2,721 Straight-line rent adjustments (2,377 ) (1,297 ) (4,768 ) (2,473 ) Amortization of deferred financing costs 721 577 1,373 1,029 Amortization of fees on real estate related notes receivable (24 ) — (24 ) — Stock-based compensation 1,249 1,163 2,510 1,624 AFFO (1) $ 29,997 $ 30,845 $ 59,445 $ 69,130 Expand ______________________ (1) The six months ended June 30, 2024 include $4,098,000 of lease termination fee income received. (2) The six months ended June 30, 2024 include a $2,000,000 severance fee received from GenesisCare, which will be recognized in rental revenues over the remaining GenesisCare amended master lease term. Expand Funds From Operations (FFO) FFO is calculated consistent with the National Association of Real Estate Investment Trusts, or Nareit's, definition, as net income (calculated in accordance with GAAP), excluding gains and losses from sales of real estate assets, impairment of real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity, and depreciation and amortization of real estate assets. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect FFO on the same basis. We do not have any investments in unconsolidated partnerships or joint ventures. We believe FFO provides a useful understanding of our performance to investors and to our management, and when compared to year over year, FFO reflects the impact on our operations from trends in occupancy. It should be noted, however, that other REITs may not define FFO in accordance with the current Nareit definition or may interpret the current Nareit definition differently than the Company does, making comparisons less meaningful. Core FFO The Company believes Core FFO is a supplemental financial performance measure that provides investors with additional information to understand the Company's sustainable performance. The Company calculates Core FFO by adjusting FFO to remove the effect of certain GAAP non-cash income and expense items, unusual and infrequent items that are not expected to impact its operating performance on an ongoing basis, items that affect comparability to prior periods and/or items that are not related to its core real estate operations. Excluded items include listing-related expenses, severance, write-off of straight-line rent receivables related to prior periods, accelerated stock-based compensation, amortization of above- and below-market lease intangibles (including ground leases), loss on extinguishment of debt and changes in the current expected credit loss reserve. Other REITs may use different methodologies for calculating Core FFO and, accordingly, the Company's Core FFO may not be comparable to other REITs. AFFO The Company believes AFFO is a supplemental financial performance measure that provides investors appropriate supplemental information to evaluate the ongoing operations of the Company. AFFO is a metric used by management to evaluate the Company's dividend policy. The Company calculates AFFO by further adjusting Core FFO for the following items: deferred rent, current period straight-line rent adjustments, amortization of deferred financing costs, amortization of fees on our real estate related notes receivable, and stock-based compensation. Other REITs may use different methodologies for calculating AFFO and, accordingly, the Company's AFFO may not be comparable to other REITs. FFO, Core FFO and AFFO should not be considered to be more relevant or accurate than the GAAP methodology in calculating net income or in its applicability in evaluating the Company's operational performance. The method used to evaluate the value and performance of real estate under GAAP should be considered a more relevant measure of operating performance and more prominent than the non-GAAP FFO, Core FFO and AFFO measures and the adjustments to GAAP in calculating FFO, Core FFO and AFFO. ______________________ (1) The six months ended June 30, 2024 include a $2,000,000 severance fee received from GenesisCare, which will be recognized in rental revenues over the remaining GenesisCare amended master lease term. (2) The six months ended June 30, 2024 include $4,098,000 of lease termination fee income received. (3) The six months ended June 30, 2024 include $1,471,000 of the total $2,000,000 severance fee received from GenesisCare, which will be recognized in rental revenues over the remaining GenesisCare amended master lease term. (4) The six months ended June 30, 2024 include $529,000 of the total $2,000,000 severance fee received from GenesisCare, which will be recognized in rental revenues over the remaining GenesisCare amended master lease term. Expand NOI The Company defines net operating income, or NOI, a non-GAAP financial measure, as rental revenue, less rental expenses, on an accrual basis. Same Store Properties In order to evaluate the overall portfolio, management analyzes the NOI of same store properties. The Company defines "same store properties" as properties that were owned and operated for the entirety of both calendar periods being compared and excludes properties under development, re-development, or classified as held for sale. By evaluating same store properties, management is able to monitor the operations of the Company's existing properties for comparable periods to measure the performance of the current portfolio and readily observe the expected effects of new acquisitions and dispositions on net income. There were 130 same store properties for the quarters ended June 30, 2025 and 2024. Cash NOI The Company defines Cash NOI as NOI for its properties excluding the impact of GAAP adjustments to rental revenue and rental expenses, consisting of straight-line rent adjustments, net of write-offs, amortization of above- and below-market lease intangibles (including ground leases) and internal property management fees, then including deferred rent received in cash. Cash NOI is used to evaluate the cash-based performance of the Company's real estate portfolio. Same store Cash NOI is calculated to exclude non-same store Cash NOI. The Company believes that NOI and Cash NOI both serve as useful supplements to net income because they allow investors and management to measure unlevered property-level operating results and to compare these results to the comparable results of other real estate companies on a consistent basis. Other real estate companies may use different methodologies for calculating Cash NOI and, accordingly, the Company's Cash NOI may not be comparable to other real estate companies. The Company uses both NOI and Cash NOI to make decisions about resource allocations and to assess the property-level performance of the real estate portfolio.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store